2 - TI Pharma

treating patients with GC therapy. As such, the thiazolidinedione troglitazone was shown to
prevent GC-induced glucose intolerance in healthy humans [46]. Troglitazone, however, is
no longer available for use in humans, and therefore a search for other options to alleviate
GC-induced insulin resistance seems justified. In this regard, the current development of
the so called dissociated glucocorticoid receptor agonists, which aim to separate the antiinflammatory
and dysmetabolic effects of GCs, may be highly interesting [47].
Acknowledgements
This paper was written within the framework of project T1-106 of the Dutch Top Institute
Pharma.
165
8
Chapter 8